5DEX-0509R / Sumitomo Pharma - LARVOL DELTA

Increased expression of tertiary lymphoid structure related genes contributes the strong anti-tumor activity of 5DEX-0509R that is dextran conjugated TLR7 agonist targeting TAM (AACR 2025) - "These data suggest that the strong polarization of TAMs into an M1-like phenotype by 5DEX-0509R triggers the change of the tumor immune microenvironment towards the formation of early TLSs. Furthermore, B cells in the tumor contribute to the anti-tumor activity of 5DEX-0509R. We believe our 5DEX-0509R would be a novel treatment option for cancer patients."

IO biomarker • Late-breaking abstract • Oncology • CCL19 • CXCL12 • CXCL13 • ICAM1 • IL21 • VCAM1